VerifyNow

WikiDoc Resources for VerifyNow
Articles
Most recent articles on VerifyNow Most cited articles on VerifyNow Review articles on VerifyNow Articles on VerifyNow in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on VerifyNow Images of VerifyNow Photos of VerifyNow Podcasts & MP3s on VerifyNow Videos on VerifyNow
Evidence Based Medicine
Cochrane Collaboration on VerifyNow Bandolier on VerifyNow TRIP on VerifyNow
Clinical Trials
Ongoing Trials on VerifyNow at Clinical Trials.gov Trial results on VerifyNow Clinical Trials on VerifyNow at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on VerifyNow NICE Guidance on VerifyNow NHS PRODIGY Guidance FDA on VerifyNow CDC on VerifyNow
Books
Books on VerifyNow
News
VerifyNow in the news Be alerted to news on VerifyNow News trends on VerifyNow
Commentary
Blogs on VerifyNow
Definitions
Definitions of VerifyNow
Patient Resources / Community
Patient resources on VerifyNow Discussion groups on VerifyNow Patient Handouts on VerifyNow Directions to Hospitals Treating VerifyNow Risk calculators and risk factors for VerifyNow
Healthcare Provider Resources
Symptoms of VerifyNow Causes & Risk Factors for VerifyNow Diagnostic studies for VerifyNow Treatment of VerifyNow
Continuing Medical Education (CME)
CME Programs on VerifyNow
International
VerifyNow en Espanol VerifyNow en Francais
Business
VerifyNow in the Marketplace Patents on VerifyNow
Experimental / Informatics
List of terms related to VerifyNow

Associate Editors-in-Chief: Davide Capodanno, M.D. [1]

Overview

The VerifyNow system (Accumetrics, San Diego, Ca, USA; [2]) is a bedside test that allows for monitoring of the efficacy of thienopyridines, aspirin, and glycoprotein IIbIIIa inhibitors. Formerly known as the Ultegra rapid platelet function analyzer, the VerifyNow system is a turbidimetric based optical detection system which measures platelet induced aggregation as an increase in light transmittance. This system is a point-of-care and consists of an instrument, a disposable assay device and controls. The assay device contains a lyophilized preparation of human fibrinogen-coated beads, platelet agonist, preservative and buffer. Three assays are currently available, which differ according to the platelet agonist contained in the mixing chamber:

Assay device	Platelet agonist	Drug(s) of interest
VerifyNow GP IIb/IIIa	Thombin receptor-activating peptide (TRAP) [iso-TRAP]	Abciximab, eptifibatide, tirofiban
VerifyNow Aspirin	Arachidonic acid	Aspirin
VerifyNow P2Y12	Adenosine diphosphate	Clopidogrel, prasugrel

After activation, the GP IIb/IIIa receptors on platelets will bind to the fibrinogen-coated microbeads and cross link to other microbeads resulting in a clearing of the beads and platelets within the detection well. The instrument uses light transmittance to measure the rate at which this clearing occurs. The main advantage of this test is that the patient sample is a low sample volume of 3.2% citrated whole blood, which is automatically dispensed from the blood collection tube into the assay device by the instrument, with no blood handling required by the user. Another advantage is that the instrument provides the results in minutes.

Template:WH Template:WS